Skip to main content

Table 2 Summary of extracted outcome data and pooled analysis

From: Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis

Study

LM ORR (%)

 

LM DCR (%)

 

PFS (moths)

 

OS (moths)

1-y OS rate

(%)

Median

95% CI

Median

95% CI

Median

95% CI

Median

95% CI

Yang 2019

62 (23/37)

45–78

 

95 (35/37)

82–99

 

8.6

5.4–13.7

 

11.0

8.0–18.0

48.8

Lee 2020

NA

NA

 

NA

NA

 

NA

NA

 

17.0

15.1–18.9

61.8

Ahn 2020

55 (12/22)

32–76

 

91 (20/22)

NA

 

11.1

4.6-NR

 

18.8

6.3-NR

63.6

Park 2020

12.5 (5/40)

NA

 

92.5 (37/40)

NA

 

8.0

7.2-NR

 

13.3

9.1-NR

55.0

Nanjo 2017

NA)

NA

 

NA

NA

 

NA

NA

 

NR

NA

NA

Zheng 2020

38.2 (13/34)

NA

 

NA

NA

 

15.6a

4.0–17.2a

 

NA

NA

NA

   

7.0b

4.0–10.0b

 

Saboundji 2018

NA

NA

 

NA

NA

 

17.3

2.7–20.8

 

18.0

4.4–23.8

65.0

Reungwetwattana 2018

80 (4/5)

NA

 

100 (5/5)

NA

 

NA

NA

 

NA

NA

NA

Akazawa 2019

33.3 (2/6)

NA

 

83.3 (5/6)

NA

 

3.7

NA

 

NR

NA

NA

Ahn 2019

25 (10/40)

NA

 

90 (36/40)

NA

 

NA

NA

 

13.2

NA

NA

Andrew 2020

NA

NA

 

NA

NA

 

5.8

1.7–9.0

 

NA

NA

NA

Meta-analysis

42

24–59

 

90

85–94

 

NA

NA

 

NA

NA

59 (53–65)

  1. CI: confidence interval; DCR: disease control rate; LM: leptomeningeal metastases; NA: not available; ORR: overall response rate; OS: overall survival; PFS: progression free survival
  2. aT790M + patients
  3. bT790M- patients